Anti-spike antibody response to natural SARS-CoV-2 infection in the general population.

Adult Aged Antibodies, Viral / immunology Antibody Formation / immunology Bayes Theorem COVID-19 / immunology Female Humans Immunoglobulin G / metabolism Male Middle Aged SARS-CoV-2 / immunology

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
29 10 2021
Historique:
received: 02 07 2021
accepted: 06 10 2021
entrez: 30 10 2021
pubmed: 31 10 2021
medline: 16 11 2021
Statut: epublish

Résumé

Understanding the trajectory, duration, and determinants of antibody responses after SARS-CoV-2 infection can inform subsequent protection and risk of reinfection, however large-scale representative studies are limited. Here we estimated antibody response after SARS-CoV-2 infection in the general population using representative data from 7,256 United Kingdom COVID-19 infection survey participants who had positive swab SARS-CoV-2 PCR tests from 26-April-2020 to 14-June-2021. A latent class model classified 24% of participants as 'non-responders' not developing anti-spike antibodies, who were older, had higher SARS-CoV-2 cycle threshold values during infection (i.e. lower viral burden), and less frequently reported any symptoms. Among those who seroconverted, using Bayesian linear mixed models, the estimated anti-spike IgG peak level was 7.3-fold higher than the level previously associated with 50% protection against reinfection, with higher peak levels in older participants and those of non-white ethnicity. The estimated anti-spike IgG half-life was 184 days, being longer in females and those of white ethnicity. We estimated antibody levels associated with protection against reinfection likely last 1.5-2 years on average, with levels associated with protection from severe infection present for several years. These estimates could inform planning for vaccination booster strategies.

Identifiants

DOI: 10.1038/s41467-021-26479-2 PMID: 34716320 PMC: PMC8556331
pubmed: 34716320
doi: 10.1038/s41467-021-26479-2
pii: 10.1038/s41467-021-26479-2
pmc: PMC8556331
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6250

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00008/6
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/22
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V001329/1
Pays : United Kingdom

Investigateurs

Tina Thomas (T)
Duncan Cook (D)
Daniel Ayoubkhani (D)
Russell Black (R)
Antonio Felton (A)
Megan Crees (M)
Joel Jones (J)
Lina Lloyd (L)
Esther Sutherland (E)
Emma Pritchard (E)
Karina-Doris Vihta (KD)
George Doherty (G)
James Kavanagh (J)
Kevin K Chau (KK)
Stephanie B Hatch (SB)
Daniel Ebner (D)
Lucas Martins Ferreira (LM)
Thomas Christott (T)
Wanwisa Dejnirattisai (W)
Juthathip Mongkolsapaya (J)
Sarah Cameron (S)
Phoebe Tamblin-Hopper (P)
Magda Wolna (M)
Rachael Brown (R)
Richard Cornall (R)
Gavin Screaton (G)
Katrina Lythgoe (K)
David Bonsall (D)
Tanya Golubchik (T)
Helen Fryer (H)
Stuart Cox (S)
Kevin Paddon (K)
Tim James (T)
Thomas House (T)
Julie Robotham (J)
Paul Birrell (P)
Helena Jordan (H)
Tim Sheppard (T)
Graham Athey (G)
Dan Moody (D)
Leigh Curry (L)
Pamela Brereton (P)
Ian Jarvis (I)
Anna Godsmark (A)
George Morris (G)
Bobby Mallick (B)
Phil Eeles (P)
Jodie Hay (J)
Harper VanSteenhouse (H)
Jessica Lee (J)
Sean White (S)
Tim Evans (T)
Lisa Bloemberg (L)
Katie Allison (K)
Anouska Pandya (A)
Sophie Davis (S)
David I Conway (DI)
Margaret MacLeod (M)
Chris Cunningham (C)

Informations de copyright

© 2021. The Author(s).

Références

EClinicalMedicine. 2020 Dec;29:100651
pubmed: 33235985
Lancet Microbe. 2021 Jun;2(6):e240-e249
pubmed: 33778792
Clin Infect Dis. 2021 Aug 2;73(3):e531-e539
pubmed: 32745196
Cell Host Microbe. 2020 Sep 9;28(3):445-454.e6
pubmed: 32585135
J Appl Lab Med. 2020 Sep 1;5(5):908-920
pubmed: 32428207
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
J Virol. 2021 Jan 13;:
pubmed: 33441348
Nat Med. 2021 Aug;27(8):1370-1378
pubmed: 34108716
Lancet Public Health. 2021 Jan;6(1):e30-e38
pubmed: 33308423
Clin Infect Dis. 2021 Mar 08;:
pubmed: 33693643
J Infect Dis. 2021 Feb 13;223(3):389-398
pubmed: 33140086
Clin Chem Lab Med. 2020 Aug 31;58(12):2131-2140
pubmed: 32866113
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Br J Haematol. 2021 Mar;192(6):1100-1105
pubmed: 33314018
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Science. 2021 Feb 26;371(6532):916-921
pubmed: 33479118
Gut. 2021 May;70(5):865-875
pubmed: 33753421
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Nat Med. 2020 Nov;26(11):1680-1681
pubmed: 33093682
Eur J Immunol. 2021 Jan;51(1):180-190
pubmed: 33259646
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
J Clin Virol. 2021 Mar;136:104765
pubmed: 33636554
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):193-196
pubmed: 33385765
PLoS One. 2020 Oct 21;15(10):e0241104
pubmed: 33085715
J Microbiol Immunol Infect. 2021 Feb;54(1):144-146
pubmed: 33046418
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
J Infect Dis. 2021 Sep 17;224(6):983-988
pubmed: 33693749
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709
pubmed: 33400782
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Stat Methods Med Res. 2014 Feb;23(1):74-90
pubmed: 22517270
Cell Host Microbe. 2021 Jun 9;29(6):917-929.e4
pubmed: 33984285
JAMA. 2020 Nov 3;324(17):1781-1782
pubmed: 32940635
PLoS Biol. 2018 Aug 10;16(8):e2006601
pubmed: 30096134
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Transfus Med. 2021 Jun;31(3):167-175
pubmed: 33333627
Immunity. 2020 Sep 15;53(3):487-495
pubmed: 32853545
Clin Infect Dis. 2021 Nov 2;73(9):e3066-e3073
pubmed: 33147319
Elife. 2021 Jul 12;10:
pubmed: 34250907
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
BMJ Open Respir Res. 2021 Sep;8(1):
pubmed: 34561239
J Infect Dis. 2021 Feb 3;223(2):197-205
pubmed: 33535236
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
J Infect Dis. 2020 Sep 14;222(8):1265-1269
pubmed: 32726417
J Med Virol. 2020 Oct;92(10):2050-2054
pubmed: 32383183

Auteurs

Jia Wei (J)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Philippa C Matthews (PC)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.

Nicole Stoesser (N)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.
The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
ORCID: 0000-0002-4508-7969

Thomas Maddox (T)

Office for National Statistics, Newport, UK.

Luke Lorenzi (L)

Office for National Statistics, Newport, UK.

Ruth Studley (R)

Office for National Statistics, Newport, UK.

John I Bell (JI)

Office of the Regius Professor of Medicine, University of Oxford, Oxford, UK.

John N Newton (JN)

Health Improvement Directorate, Public Health England, London, UK.

Jeremy Farrar (J)

Wellcome Trust, London, UK.

Ian Diamond (I)

Office for National Statistics, Newport, UK.

Emma Rourke (E)

Office for National Statistics, Newport, UK.

Alison Howarth (A)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.
The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

Brian D Marsden (BD)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Sarah Hoosdally (S)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

E Yvonne Jones (EY)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

David I Stuart (DI)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Derrick W Crook (DW)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.
The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

Tim E A Peto (TEA)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.
The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

Koen B Pouwels (KB)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.
Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
ORCID: 0000-0001-7097-8950

A Sarah Walker (AS)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.
MRC Clinical Trials Unit at UCL, UCL, London, UK.

David W Eyre (DW)

Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK. david.eyre@bdi.ox.ac.uk.
Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK. david.eyre@bdi.ox.ac.uk.
The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK. david.eyre@bdi.ox.ac.uk.
The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. david.eyre@bdi.ox.ac.uk.
ORCID: 0000-0001-5095-6367

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Anti-spike antibody response to natural...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Anti-spike antibody response to natural...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Anti-spike antibody response to natural...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité active › Production d'anticorps › Anti-spike antibody response to natural...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Théorème de Bayes › Anti-spike antibody response to natural...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Anti-spike antibody response to natural...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Anti-spike antibody response to natural...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline G › Anti-spike antibody response to natural...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Anti-spike antibody response to natural...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Anti-spike antibody response to natural...